Open AccessCariprazine in Three Special Different Areas: A Real-World Experience
Author(s) -
Camilla Gesi,
Silvia Paletta,
Marco Palazzo,
Bernardo Dell’Osso,
Claudio Mencacci,
Giancarlo Cerveri
Publication year - 2021
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s335332
Subject(s) - medicine , partial agonist , akathisia , antipsychotic , dopamine receptor d3 , schizophrenia (object oriented programming) , tolerability , extrapyramidal symptoms , bipolar i disorder , psychiatry , bipolar disorder , adverse effect , dopamine receptor d2 , agonist , mood , dopamine , mania , receptor
Cariprazine is an antipsychotic medication which received approval from the US Food and Drug Administration for the treatment of schizophrenia in September 2015. Cariprazine is a dopamine D 3 and D 2 receptor partial agonist, with a preference for the D 3 receptor. Furthermore, although to a more limited extent, cariprazine also exhibits partial agonism at the level of 5-HT 1A receptors, thus exerting an antidepressant effect in addition to the antipsychotic effect. The most commonly encountered adverse events are extrapyramidal symptoms and akathisia. Short-term weight gain appears infrequently. Cariprazine is not associated with any clinically meaningful alterations in metabolic variables, prolactin, or ECG QT interval. Cariprazine is also approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder. Clinical trials of cariprazine are ongoing in patients with acute bipolar I depression and as adjunctive treatment to antidepressant therapy in patients with major depressive disorder. In this article, we present some significant clinical cases regarding the use of cariprazine, with the hope that our experience can provide insight or suggestions to be used in clinical practice.